ACROBiosystems
Newark
About ACROBiosystems
ACROBiosystems develops recombinant antigens for emergency SARS-CoV-2 variants. They also produce a series of GMP-grade cytokines under the GMP-quality management system. Their products include fc receptor proteins, immune checkpoint proteins, llama IgG fc fusion proteins, biomarkers, CD antigens, and more.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 251 – 500
- Estimated revenue: $100K – $500K
- Funding stage: Early Stage Venture
- Last round: Series B (Jan 2020)
- Website: acrobiosystems.com
- Phone: +1 800-810-0816
Industries & Categories
Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/acrobiosystems-182724 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.